CzMA JEP Home page CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ
Journals - Article
CzMA JEP Home page News About Assocation Publishing Division Medical Journals Searching Supplements Catalogue
 
  Čes. a Slov. Neurol. Neurochir., 61/94, 1998, No. 6, p. 291–295.
 
Antiepileptic Pharmacotherapy with Sustained Release Sodium Valproate Post Marketing Surveillance of Orfiril® 300 retard 
B. J. Steinhoff 

Klinik und Poliklinik für Neurologie, Georg-August-Universität Göttingen
 


Summary:

       A three-month post marketing surveillance investigated the efficacy and tolerability of the sustained release sodium valproate formulation (Orfiril ® retard) in 366 patients with primary generalised or focal seizures. 87 patients were newly diagnosed drug-naive patients, 116 patients had received prior antiepileptic treatment except valproate and 163 patients were receiving conventional valproate preparations. The seizure frequency was reduced and the number of seizure-free patients increased in all subgroups during the observation period. The incidence of adverse events with 16% was lower than under previous therapy. The results of the study show that sustained release valproate can be initially introduced successfully in newly diagnosed patients. Patients who are not seizure-free under other antiepileptic medication benefit from valproate treatment. Patients under conventional valproate therapy may be switched to the same daily dose of sustained release valproate which is administered in a more convenient b.i.d. or once daily dose regimen. This improves the clinical efficacy and tolerability and results in better patient acceptance and compliance.

        Key words: epilepsy, pharmacotherapy, sodium valproate
       

Order this issue

  BACK TO CONTENTS  
 
 
| HOME PAGE | CODE PAGE | CZECH VERSION |
©  1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o.
WEBMASTER